Erin Michael

Healio spoke with Chakra Chaulagain, MD, about phase 3 PERSEUS trial results presented at ASH 2023.

BOSTON — Healio spoke with James L. Boyer, MD, FACEP, about interim results from the phase 2a INTEGRIS-PSC trial presented at The Liver Meeting, which showed bexotegrast reduced biomarkers of liver fibrosis vs. placebo.The ongoing phase 2 study is assessing bexotegrast in patients with primary sclerosing cholangitis and suspected liver fibrosis, and evaluating its safety, tolerability and

BOSTON — Patients with metabolic dysfunction-associated steatotic liver disease who underwent bariatric surgery lost less weight over 5 years than those without MASLD, according to research presented at The Liver Meeting.“Individuals with MASLD at baseline lost less total weight,” Monica Tincopa, MD, MS, a gastroenterologist, transplant hepatologist and assistant professor of

MADRID — This year’s ESMO Congress included research updates that provide valuable data on chemotherapy-free treatment options being explored in recurrent ovarian cancer. Kosei Hasegawa, MD, PhD, associate professor at Saitama Medical University International Medical Center, said during a discussion on data presented from two trials — phase 3 results from NRG-GY004 and

BOSTON — Healio spoke with James L. Boyer, MD, about phase 3 findings from the RESPONSE trial and the ELATIVE trial and presented at The Liver Meeting.

Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting. “The consumption of ultra-processed foods (UPF) has increased dramatically over the past two decades and has been associated with obesity, type 2 diabetes,

Healio spoke with Nikki Yuill, LCSW, and Michelle Rajotte, LMSW, the director and associate director of The Leukemia & Lymphoma Society’s Information Resource Center, about the importance of supportive care in young adults with leukemia.

Healio spoke with Hossein Borghaei, DO, MS, about results from the SAPPHIRE trial presented at this year’s ESMO Congress.“Unfortunately, we realized that for our patients who are being treated upfront with a combination of chemotherapy and immunotherapy, at the time of disease progression, their options are rather limited,” Borghaei, chief of thoracic medical oncology, professor

Healio spoke with Melina Elpi Marmarelis, MD, about key takeaways from the MARS 2 trial presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

Melina Elpi Marmarelis, MD, discussed research on the use of osimertinib versus durvalumab following chemoradiation in patients with stage III EGFR-mutated NSCLC.